StreetInsider.com News Articles

Form SCHEDULE 13G Yarrow Bioscience, Inc. Filed by: Invus Global Management, LLC

Thu, 17 Sep 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260917/27076608.html

Yarrow Bioscience closes $172.5M public offering on Nasdaq

Mon, 14 Sep 2026 16:05:50 -0400

Yarrow Bioscience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company, announced the closing of an underwritten public offering of 6,634,615 shares of common stock at $26.00 per share, generating approximately $172.5 million in gross proceeds before deductions for underwriting discounts, commissions, and other fees.

The offering included the full exercise of an underwriters' option to purchase 865,384 additional shares. All securities were offered by Yarrow Bioscience.

According to a press release, the company intends to use net proceeds to fund research and development expenses for its pipeline and for general corporate purposes, which may include working capital and capital expenditures.

Jefferies, TD Cowen, and

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Mon, 14 Sep 2026 16:05:00 -0400

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the closing of its previously announced underwritten public offering of 6,634,615 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 865,384 additional shares, at a public offering price per share of $26.00. The aggregate gross proceeds to Yarrow from the offering were approximately $172.5 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Yarrow.

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Mon, 14 Sep 2026 16:05:00 -0400

Form 8-K Yarrow Bioscience, Inc. For: Sep 10

Mon, 14 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260914/27058297.html

Form 424B5 Yarrow Bioscience, Inc.

Fri, 11 Sep 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260911/27053483.html

Form 424B5 Yarrow Bioscience, Inc.

Fri, 11 Sep 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260911/27053393.html

Yarrow Bioscience prices $150M public offering at $26 per share

Thu, 10 Sep 2026 21:11:12 -0400

Yarrow Bioscience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company, has priced an underwritten public offering of 5,769,231 shares of common stock at $26.00 per share, according to a press release from the company.

The offering is expected to generate approximately $150 million in gross proceeds before underwriting discounts, commissions, and other expenses. The offering is expected to close on September 14, 2026, subject to customary closing conditions.

Yarrow has also granted underwriters a 30-day option to purchase up to an additional 865,384 shares at the public offering price, less underwriting discounts and commissions.

The company said it intends to use the net proceeds

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

Thu, 10 Sep 2026 21:11:00 -0400

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of its previously announced underwritten public offering of 5,769,231 shares of its common stock at a public offering price per share of $26.00. The aggregate gross proceeds to Yarrow from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Yarrow, excluding any exercise of the underwriters’ option to purchase additional shares. The

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

Thu, 10 Sep 2026 21:11:00 -0400

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of its previously announced underwritten public offering of 5,769,231 shares of its common stock at a public offering price per share of $26.00. The aggregate gross proceeds to Yarrow from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Yarrow, excluding any exercise of the underwriters’ option to purchase additional shares. The

Yarrow Bioscience launches underwritten public stock offering

Thu, 10 Sep 2026 16:03:14 -0400

Yarrow Bioscience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company, announced the commencement of an underwritten public offering of shares of its common stock, with an option for certain investors to receive pre-funded warrants in lieu of common stock.

The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price, less underwriting discounts and commissions. All securities are being offered by Yarrow.

Yarrow stated it intends to use net proceeds to fund research and development expenses for its pipeline and for general corporate purposes, which may include working capital and capital

Yarrow Bioscience Announces Proposed Underwritten Public Offering

Thu, 10 Sep 2026 16:03:00 -0400

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Yarrow expects to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock at the public offering price, less underwriting discounts and commissions. The

Yarrow Bioscience Announces Proposed Underwritten Public Offering

Thu, 10 Sep 2026 16:03:00 -0400

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Yarrow expects to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock at the public offering price, less underwriting discounts and commissions. The

Form 8-K Yarrow Bioscience, Inc. For: Sep 10

Thu, 10 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260910/27048282.html

Form EFFECT Yarrow Bioscience, Inc.

Thu, 20 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260820/26952355.html

Form EFFECT Yarrow Bioscience, Inc.

Thu, 20 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260820/26952355.html

Form SCHEDULE 13G Yarrow Bioscience, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:33:00 -0400

si-local-file:///var/storage/secattach/20260814/26933329.html

Form SCHEDULE 13G Yarrow Bioscience, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:33:00 -0400

si-local-file:///var/storage/secattach/20260814/26933329.html

Form SCHEDULE 13G Yarrow Bioscience, Inc. Filed by: venBio Global Strategic Fund V, L.P.

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931912.html

Form SCHEDULE 13G Yarrow Bioscience, Inc. Filed by: venBio Global Strategic Fund V, L.P.

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931912.html

Form POS AM Yarrow Bioscience, Inc.

Fri, 14 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26923892.html

Form POS AM Yarrow Bioscience, Inc.

Fri, 14 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26923892.html

Form 8-K/A Yarrow Bioscience, Inc. For: Jul 24

Thu, 13 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26921306.html

Form 8-K/A Yarrow Bioscience, Inc. For: Jul 24

Thu, 13 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26921306.html

Form 10-Q Yarrow Bioscience, Inc. For: Jun 30

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920627.html